Company Overview and News


Add 500288
to your dashboard

Headline News

Morepen Laboratories Limited - Trading Window

2018-01-12 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

Morepen Laboratories Limited

2017-12-20 thehindubusinessline
The United States Food and Drug Administration (US FDA) has cleared Montelukast Sodium, a bulk drug/ API manufactured by Morepen Laboratories, for sale in the US market. This gives Morepen an entry into the ₹2,000-crore (approx. $300 million) US market for Montelukast. The first commercial orders for the bulk drug are expected in Q2 FY 2018-19. Shares of Morepen Labs jumped 20 per cent at ₹30.30 on the BSE.

Sensex ends rangebound session lower, Nifty fails to hold 10,450; Realty, Midcap shine

2017-12-20 moneycontrol
Equity benchmarks closed rangebound session mildly lower on Wednesday but the broader markets continued their run-up for fifth consecutive trading day. (16-0)

Morepen gets US FDA clearance for anti-asthmatic drug Montelukast

2017-12-20 business-standard
The United States Food and Drug Administration (USFDA) has cleared Montelukast Sodium, a bulk drug / API manufactured by Morepen Laboratories Ltd., for sale in the US market. This gives Morepen an entry into the Rs. 2000 crore (Approx. $ 300 million) US market for Montelukast. The first commercial orders for the bulk drug are expected in Q2 of FY 2018-19.

Morepen shares spike 18% on USFDA approval for Montelukast

2017-12-20 thehindubusinessline
Shares of Morepen Laboratories surged nearly 18 per cent after the company said the US health regulator has given approval to sell Montelukast Sodium, used in managing asthma symptoms and seasonal allergies, in the US market.

Morepen Labs gets USFDA nod for asthma drug

2017-12-20 moneycontrol
Morepen Laboratories today said the US health regulator has given approval to Montelukast Sodium, used in managing asthma symptoms and seasonal allergies, for sale in the US market.

Morepen Lab hits 52-week high on USFDA clearance for Montelukast Sodium

2017-12-20 moneycontrol
Share price of Morepen Laboratories touched 52-week high of Rs 29.40, rising 16.4 percent intraday Wednesday as it has received USFDA clearance for its bulk drug Montelukast Sodium.

Morepen Laboratories Limited - Press Release

2017-12-20 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

Morepen Laboratories Limited - Press Release

2017-11-10 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information. (15-0)

Morepen Labs inks pact with Belgian firm Vesale Pharma

2017-11-09 thehindubusinessline
Morepen Laboratories today said it has signed an agreement with Belgian firm Vesale Pharma to strengthen its presence in the probiotics segment.

Morepen Laboratories Limited - News Verification

2017-11-09 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information. (15-0)

Morepen Laboratories Limited - Press Release

2017-11-09 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information. (15-0)

Morepen Laboratories Limited - News Verification

2017-11-09 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information. (15-0)